{
    "clinical_study": {
        "@rank": "126001", 
        "acronym": "HIV", 
        "arm_group": [
            {
                "arm_group_label": "Part A-Group 1: BMS-955176 (5 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 5 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part A-Group 2: BMS-955176 (10 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 10 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part A-Group 3: BMS-955176 (20 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 20 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part A-Group 4: BMS-955176 (40 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 40 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part B-Group 5: BMS-955176 + Atazanavir", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 40 mg solution by mouth once daily for 28 days\nAtazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
            }, 
            {
                "arm_group_label": "Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 40 mg solution by mouth once daily for 28 days\nAtazanavir 1 x 300 mg capsules by mouth once daily for 28 days\nRitonavir 1 x 100 mg tablet by mouth once daily for 28 days"
            }, 
            {
                "arm_group_label": "Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine", 
                "arm_group_type": "Experimental", 
                "description": "Atazanavir 1 x 300 mg capsule by mouth once daily for 28 days\nRitonavir 1 x 100 mg tablet by mouth once daily for 28 days\nTenofovir 1 x 300 mg tablet by mouth once daily for 28 days\nEmtricitabine 1 x 200 mg capsule once daily for 28 days"
            }, 
            {
                "arm_group_label": "Part C-Group 8: BMS-955176 (40 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 40 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part A-Group 9: BMS-955176 (80 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 80 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part A-Group 10: BMS-955176 (120 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 120 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }, 
            {
                "arm_group_label": "Part A-Group 11 (Optional): BMS-955176 (\u2264120 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 \u2264120 mg solution by mouth once daily for 14 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 14 days"
            }, 
            {
                "arm_group_label": "Part B-Group 12: BMS-955176 (80 mg) + Atazanavir", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 80 mg solution by mouth once daily for 28 days\nAtazanavir 2 x 200 mg capsules by mouth once daily for 28 days"
            }, 
            {
                "arm_group_label": "Part C-Group 13: BMS-955176 (120 mg) or Placebo", 
                "arm_group_type": "Experimental", 
                "description": "BMS-955176 120 mg solution by mouth once daily for 10 days\nOR\nPlacebo matching with BMS-955176 0 mg solution by mouth once daily for 10 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to study the safety and tolerability of a HIV drug and\n      to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected\n      patients"
        }, 
        "brief_title": "Study to Evaluate a HIV Drug for the Treatment of HIV Infection", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-1 Infection", 
        "condition_browse": {
            "mesh_term": "HIV Infections"
        }, 
        "detailed_description": {
            "textblock": "Masking: Open-Part B. Double Blind-Parts A and C\n\n      Gender: Both female and male participants for Parts A and C. Male participants for Part B.\n\n      HIV = Human Immunodeficiency Virus RNA = Ribonucleic acid"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Age 18-55 years inclusive\n\n          -  Men and women: (Parts A and C); men only (Part B)\n\n          -  Women of childbearing potential (WOCBP) must not be pregnant and nursing\n\n          -  BMI: 18.0-35.0 kg/m2\n\n          -  Subjects are infected with HIV-1 (clades B or C) and meet following criteria at the\n             screening:\n\n             i) Plasma HIV-1 RNA \u22655,000 copies/mL; ii) Antiretroviral treatment naive (defined as\n             <1 week of ARV treatment) or ART-experienced (protease inhibitor and/or maturation\n             inhibitor naive); iii) Subjects are not eligible for HIV-1 treatment based on the\n             United States Department of Health and Human Services Panel on Antiretroviral\n             Guidelines for Adults and Adolescents or have declined initiation of cART iv) CD4+\n             lymphocyte measurement \u2265200 cells/\u03bcL; v) In Parts A and B, all subjects are infected\n             with HIV-1 clade B vi) In Part C, all subjects are infected with HIV-1 clade C\n\n        Exclusion Criteria:\n\n          -  History of genotypic and/or phenotypic drug resistance testing showing resistance to\n             protease inhibitors\n\n          -  Any significant acute or chronic medical illness which is not stable or is not\n             controlled with medication or not consistent with HIV-1 infection\n\n          -  Receive antiretroviral treatment within 12 weeks prior to screening\n\n          -  Currently co-infected with hepatitis C or hepatitis B\n\n          -  Previously received an HIV maturation inhibitor or HIV protease inhibitor\n\n          -  Current or recent (within 3 months of study drug administration) gastrointestinal\n             disease\n\n          -  Any major surgery within 4 weeks of study drug administration\n\n          -  Acute diarrhea lasting \u22651 day, within 3 weeks prior to randomization\n\n          -  Subjects with history of Gilbert's syndrome\n\n          -  Subjects previously received an HIV maturation inhibitor or HIV protease inhibitor\n\n          -  A personal history of clinically relevant cardiac disease, symptomatic or\n             asymptomatic arrhythmias, syncopal episodes, or additional risk factors for torsades\n             de pointes. A personal or family history of long QT syndrome\n\n          -  Patients who are unwilling to practice adequate infection protection during and after\n             study participation to minimize potential for spread of HIV infection, including HIV\n             which may have developed resistance to HIV maturation inhibitor and/or ATV\n\n          -  Any gastrointestinal surgery that could impact upon the absorption of study drug\n\n          -  Smoking >10 cigarettes per day\n\n          -  PR \u2265210 msec; QRS \u2265120 msec; QT \u2265500 msec; and QTcF \u2265470 msec for women and \u2265450 msec\n             for men\n\n          -  Evidence of second or third degree heart block prior to study drug\n\n          -  Absolute Neutrophil Count <(ANC) 0.7 x lower limit of normal (LLN)\n\n          -  Hemoglobin <0.8 x LLN\n\n          -  Alanine aminotransferase (ALT) >1.25 x upper limit of normal (ULN)\n\n          -  Aspartate aminotransferase (AST) >1.25 x ULN\n\n          -  Total Bilirubin >1.25 x ULN\n\n          -  Creatinine clearance <60 mL/mim\n\n          -  Positive urine screen for drugs of abuse without a valid prescription (subjects\n             positive for cannabinoids and/or amphetamines will be included)\n\n          -  Positive blood screen for hepatitis C virus (HCV) RNA, hepatitis B surface antigen\n             (consistent with active or chronic hepatitis B), or HIV-2 antibody\n\n          -  History of any significant drug allergy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803074", 
            "org_study_id": "AI468-002", 
            "secondary_id": "2012-004124-38"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A-Group 1: BMS-955176 (5 mg) or Placebo", 
                    "Part A-Group 2: BMS-955176 (10 mg) or Placebo", 
                    "Part A-Group 3: BMS-955176 (20 mg) or Placebo", 
                    "Part A-Group 4: BMS-955176 (40 mg) or Placebo", 
                    "Part B-Group 5: BMS-955176 + Atazanavir", 
                    "Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir", 
                    "Part C-Group 8: BMS-955176 (40 mg) or Placebo", 
                    "Part A-Group 9: BMS-955176 (80 mg) or Placebo", 
                    "Part A-Group 10: BMS-955176 (120 mg) or Placebo", 
                    "Part A-Group 11 (Optional): BMS-955176 (\u2264120 mg) or Placebo", 
                    "Part B-Group 12: BMS-955176 (80 mg) + Atazanavir", 
                    "Part C-Group 13: BMS-955176 (120 mg) or Placebo"
                ], 
                "intervention_name": "BMS-955176", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A-Group 1: BMS-955176 (5 mg) or Placebo", 
                    "Part A-Group 2: BMS-955176 (10 mg) or Placebo", 
                    "Part A-Group 3: BMS-955176 (20 mg) or Placebo", 
                    "Part A-Group 4: BMS-955176 (40 mg) or Placebo", 
                    "Part C-Group 8: BMS-955176 (40 mg) or Placebo", 
                    "Part A-Group 9: BMS-955176 (80 mg) or Placebo", 
                    "Part A-Group 10: BMS-955176 (120 mg) or Placebo", 
                    "Part A-Group 11 (Optional): BMS-955176 (\u2264120 mg) or Placebo", 
                    "Part C-Group 13: BMS-955176 (120 mg) or Placebo"
                ], 
                "intervention_name": "Placebo matching with BMS-955176", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part B-Group 5: BMS-955176 + Atazanavir", 
                    "Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir", 
                    "Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine", 
                    "Part B-Group 12: BMS-955176 (80 mg) + Atazanavir"
                ], 
                "intervention_name": "Atazanavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part B-Group 6: BMS-955176 + Atazanavir + Ritonavir", 
                    "Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine"
                ], 
                "intervention_name": "Ritonavir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine", 
                "intervention_name": "Tenofovir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part B-Group 7: Atazanavir+Ritonavir+Tenofovir+Emtricitabine", 
                "intervention_name": "Emtricitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ritonavir", 
                "Atazanavir", 
                "Tenofovir", 
                "Tenofovir disoproxil", 
                "Emtricitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Site 0001"
            }, 
            "facility": {
                "address": {
                    "city": "Berlin", 
                    "country": "Germany", 
                    "zip": "10117"
                }, 
                "name": "Local Institution"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "13", 
        "official_title": "Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in plasma HIV-1 RNA levels from baseline (Day 1-predose) on Day 11 with monotherapy", 
            "safety_issue": "No", 
            "time_frame": "Baseline (Day 1-predose) and Day 11 after the final dose with BMS-955176"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety based on frequency of Adverse events (AEs), serious AEs, discontinuations due to AEs, findings of marked abnormalities in vital signs, clinical laboratory tests, ECG readings and physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 24 (Groups 1-4, 8-10 and 13), up to day 28 (optional group 11) and up to day 42 (Part B)"
            }, 
            {
                "measure": "Time course of the change from baseline in plasma log10 HIV-1 RNA levels and the time of maximum decrease during the 10-day monotherapy and combination therapy of BMS-955176 with Atazanavir (ATV) +/- Ritonavir (RTV)", 
                "safety_issue": "No", 
                "time_frame": "Day 1-24 (Groups 1-4, 8-10 & 13), Day 1-28 (optional group 11) and Day 1-42 (Part B)"
            }, 
            {
                "measure": "Change from baseline in CD4+ and CD8+ lymphocyte counts and percentages following monotherapy and combination therapy of BMS-955176 with ATV +/- RTV in HIV-1 infected subjects", 
                "safety_issue": "No", 
                "time_frame": "Day 1-24 (Groups 1-4, 8-10 & 13), Day 1-28 (optional group 11) and Day 1-42 (Part B)"
            }, 
            {
                "measure": "Maximum observed plasma concentration (Cmax) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Observed concentration at 24 hours postdose (C24) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Time of maximum observed plasma concentration (Tmax) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Trough observed plasma concentration (Ctrough) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Accumulation Index (AI), calculated as ratio of AUC(TAU) at steady state to AUC(TAU) after the first dose of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Terminal Plasma half-life (T-Half)-after last dose only of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "Day 10 (Part A and C), Day 14 (optional group 11) and Day 28 (Part B)"
            }, 
            {
                "measure": "Degree of Fluctuation (DF), calculated as steady state (Cmax-C24) / (AUC(TAU) / 24) of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }, 
            {
                "measure": "Average steady-state plasma concentration (Css-av), calculated as AUC(TAU) / TAU of BMS-955176", 
                "safety_issue": "No", 
                "time_frame": "26 timepoints up to Day 10 (Groups 1-4, 8-10 & 13), 30 timepoints up to Day 14 (optional group 11) and 24 timepoints up to Day 28 (Part B)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}